BridgeBio Oncology Therapeutics (BBOT) Reiterated at Buy by Stifel After Q4 Results
Tweet Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $23.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
